PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast And Market Analysis Event-Driven Update
Table 38: Product Profile - Tabalumab 76
Table 39: ACR Responses and DAS28 Scores for Tabalumab vs. Placebo at Week 16 77
Table 40: Tabalumab SWOT Analysis, 2012 78
Table 41: Product Profile - Fostamatinib 79Table 42: ACR Responses and DAS28 Scores for Fostamatinib vs. Placebo at Month Three 80 Table 43: Fostamatinib SWOT Analysis, 2012 82 Table 44: Product Profile - RAVAX 83 Table 45: RAVAX SWOT Analysis, 2012 86 Table 46: Product Profile - Secukinumab 87 Table 47: Secondary Endpoint Results for Secukinumab vs. Placebo at Weeks 24 and 52 88 Table 48: Secukinumab SWOT Analysis, 2012 90 Table 49: Product Profile - Masitinib 91 Table 50: ACR Responses for Masitinib in the ITT Population (12 Weeks) 92 Table 51: ACR Responses for Masitinib in the ITT Population (12-82 Weeks) 93 Table 52: Masitinib SWOT Analysis, 2012 95 Table 53: Product Profile - Baricitinib 96 Table 54: ACR Responses for Baricitinib + MTX vs. Placebo + MTX at Week 12 97 Table 55: Safety of 4 and 8mg Baricitinib at Week 12 98 Table 56: Laboratory Values of 4 and 8mg Baricitinib at Week 12 98 Table 57: Baricitinib SWOT Analysis, 2012 99 Table 58: Product Profile - Sarilumab 100 Table 59: MOBILITY Study Results for Sarilumab at Week 12 101 Table 60: Sarilumab SWOT Analysis, 2012 102 Table 61: Product Profile - Sirukumab 103 Table 62: Sirukumab SWOT Analysis, 2012 105 Table 63: Sales Forecasts ($m) for Rheumatoid Arthritis in the United Kingdom 107 Table 64: Key Events Impacting Sales for Rheumatoid Arthritis in the United Kingdom, 2012 109 Table 65: Rheumatoid Arthritis Market - Drivers and Barriers in the United Kingdom, 2012 109 Table 66: Key Launch Dates 124 Table 67: Key Patent Expiries 124 Table 68: Physicians Surveyed, By Country 132
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV